

## Research Article

# Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis

Matteo Monami,<sup>1</sup> Ilaria Dicembrini,<sup>2</sup> Niccolò Marchionni,<sup>1</sup>  
Carlo M. Rotella,<sup>2</sup> and Edoardo Mannucci<sup>3</sup>

<sup>1</sup>Geriatric Cardiology, Careggi Teaching Hospital and University of Florence, 50141 Florence, Italy

<sup>2</sup>Obesity Agency, Careggi Teaching Hospital and University of Florence, 50141 Florence, Italy

<sup>3</sup>Diabetes Agency, Careggi Teaching Hospital and University of Florence, 50141 Florence, Italy

Correspondence should be addressed to Edoardo Mannucci, edoardo.mannucci@unifi.it

Received 22 January 2012; Accepted 19 March 2012

Academic Editor: Giovanni Di Pasquale

Copyright © 2012 Matteo Monami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs), approved as glucose-lowering drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An extensive Medline, Cochrane database, and Embase search for “exenatide,” “liraglutide,” “albiglutide,” “semaglutide,” and “lixisenatide” was performed, collecting all randomized clinical trials on humans up to December 15, 2011, with a duration of at least 24 weeks, comparing GLP-1 receptor agonists with either placebo or active drugs. Twenty two (7,859 patients) and 7 (2,416 patients) trials with available results on body weight at 6 and 12 months, respectively, were included. When compared with placebo, GLP-1RAs determine a reduction of BMI at 6 months of  $-1.0$  [ $-1.3$ ;  $-0.6$ ]  $\text{kg}/\text{m}^2$ . Considering the average BMI at baseline ( $32.4 \text{ kg}/\text{m}^2$ ) these data means a weight reduction of about 3% at 6 months. This result could seem modest from a clinical standpoint; however, it could be affected by many factors contributing to an underestimation of the effect of GLP-1RA on body weight, such as non adequate doses, inclusion criteria, efficacy of GLP-1RA on reducing glycosuria, and association to non-pharmacological interventions not specifically aimed to weight reduction.

## 1. Introduction

Most drugs developed for the therapy of obesity have failed to show a sufficient efficacy and safety for long-term treatment. In particular, agents which stimulate energy expenditure (e.g., thyroid hormones, sympathoadrenergic drugs, or sibutramine) do not have an adequate cardiovascular safety, whereas centrally acting anorexants either are ineffective in the long term (e.g., serotonin reuptake inhibitors) or show neuropsychiatric adverse effects (e.g., amphetamine derivatives or cannabinoid receptor antagonists) [1]. As a result, orlistat, which inhibits lipid absorption, is the only available drug for obesity in many countries. Even for drugs which do not show relevant problems of long-term safety, such as orlistat, the unsatisfactory tolerability profile limits clinical use.

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, produced mainly in the postprandial phase, which

a dose-dependent fashion [2]. Due to this properties, the hormone reduces hyperglycemia without inducing hypoglycemia in patients with type 2 diabetes [3]. The rapid inactivation of GLP-1 in vivo and the consequent short half-life (a few minutes after subcutaneous administration) prevents its therapeutic use. Long-acting GLP-1 receptor agonists, which can be administered via subcutaneous injection once or twice a day or once a week, have been developed as glucose-lowering drugs for the treatment of type 2 diabetes [4], but they have also been shown to reduce body weight [5, 6]. The effects of GLP-1 and its agonists on body weight appears to be due to a reduction in food intake, mainly determined by a direct central (hypothalamic) effect of the hormone [7]. The stimulation of GLP-1 receptor also retards gastric emptying; this latter effect is again due, at least partly, to a central action, mediated via the autonomous nervous system [8]. One of the side effect of GLP-1 receptor agonists, nausea (sometimes

reducing effect; however, weight loss has also been observed when analyzing separately patients who do not report nausea [8].

In fact, some drugs of this class (i.e., liraglutide and long-acting exenatide) are currently under development for the treatment of obesity [9–12]. A phase II, 20-week trial enrolling patients without diabetes showed that liraglutide has a higher efficacy than orlistat in promoting weight loss [13]. Another longer-term (52 weeks) trial with same molecule, the results of which have not been published in full but partly disclosed [14], confirms that liraglutide is an interesting option for the treatment of obesity. Another molecule of the same class, exenatide, has been reported to induce a significant weight loss in a 24-week placebo-controlled trial [15]. Most of what is known on the effect of GLP-1 receptor agonists on body weight comes from clinical trials performed on patients with type 2 diabetes, with glucose control as the principal endpoint. Currently ongoing trials enrolling subjects with obesity and without diabetes will provide, in due time, further information. In the meanwhile, a systematic evaluation of data collected in studies on type 2 diabetes can provide a more defined picture of what we can realistically expect from GLP-1 receptor agonists as weight-reducing agents.

A recent meta-analysis has shown a weight loss of approximately 3% at endpoint in available published trials, with a duration ranging from 20 to 52 weeks [6]. This analysis does not provide information on the time-course of weight loss with GLP-1 receptor agonists. Furthermore, no distinction is made between placebo- and active comparator-controlled trials, with some of the comparators (i.e., insulin, thiazolidinediones, and sulfonylureas) possibly inducing weight gain. Aim of the present meta-analysis is to assess the effects of GLP-1 receptor agonists on body weight at 6 and 12 months of treatment, separating placebo-controlled trials from comparisons with active drugs. Furthermore, a meta-regression analysis will be performed to explore predictors of weight change during treatment.

## 2. Methods

The meta-analysis was reported following the PRISMA checklist [16].

**2.1. Data Sources, Searches, and Extraction.** An extensive Medline, Cochrane database, and Embase search for all articles in English using the keywords “exenatide”, “liraglutide”, “albiglutide”, “semaglutide”, and “lixisenatide” was performed collecting all randomized clinical trials on humans up to December 15, 2011. Completed but still unpublished trials were identified through a search of <http://www.clinicaltrials.gov/> website. FDA (<http://www.fda.gov/>) and European Medicines Agency (EMA, <http://www.ema.europa.eu/>) reviews of approved drugs, as well as published information provided to FDA in response to queries during the approval process, were also searched for retrieval of unpublished trials. Results of those trials were retrieved, if available, on <http://www.novonordisk-trials.com/> or <http://www.fda.gov/oc/ohrt/>

which were not exhaustively disclosed, an attempt was made (through e-mail) to contact principal investigators in order to retrieve missing data. For all published trials, results reported in papers were used as the primary source of information, when available.

The identification of relevant abstracts, the selection of studies based on the criteria described previously, and the subsequent data extraction were performed independently by two of the authors (E. Mannucci, M. Monami), and conflicts these resolved by the third investigator (N. Maschionni).

**2.2. Study Selection.** A meta-analysis was performed including all randomized clinical trials, with a duration of at least 24 weeks, comparing full therapeutic doses Glucagon-like Peptide-1 (GLP-1) receptor agonists (i.e., at least 1.8 mg/day liraglutide, 20 µg/day for exenatide b.i.d., 2 mg/day for exenatide once weekly) and with placebo or other active drugs. Trials with a shorter duration were excluded, due to the fact that they could not yield relevant information on body weight reduction. No review protocol was published elsewhere. Trials without any information on body mass index (BMI) at 6 or 12 months were also excluded.

**2.3. Quality Assessment.** The quality of trials was assessed using some of the parameters proposed by Jadad et al. [17]. The score was not used as a criterion for the selection of trials, whereas some items were used only for descriptive purposes.

**2.4. Data Synthesis and Analysis.** The principal outcome was the effect of full therapeutic doses of GLP-1 receptor agonists, compared with other hypoglycemic agents or placebo, on BMI at 6 months and 12 months (when available). Between-group differences in endpoint BMI were assessed as a measure of treatment effect, without considering differences from baseline. Secondary outcomes included glycated hemoglobin (HbA1c) at 6 and 12 months. Separate analyses were performed for trials with different GLP-1 receptor agonists and with different comparators, whenever possible. Furthermore, separate analyses were performed for trials with different principal endpoints. Metaregression analysis was performed on placebo-controlled trials, in order to identify possible predictors of weight loss.

Heterogeneity was calculated using the  $I^2$  statistics. Weighted mean differences were calculated for BMI and HbA1c at 6 and 12 months, and a random effects model was used for the meta-analysis. Publication/disclosure bias was estimated separately for placebo-controlled trials and studies versus active comparators, using Kendall's tau without continuity correction, and one-sided  $P$ , were calculated, together with the fail-safe  $N$ , and Funnel plot analysis. All those analyses were performed using Comprehensive Meta-analysis Version 2, Biostat, (Englewood, NJ, USA).

## 3. Results

The trial flow summary is reported in Figure 1. Trials with




FIGURE 1: Trial flow summary.




FIGURE 2: Funnel plot for bias/disclosure publication.

(19 of which in patients with diabetes), whereas those with data at one year were 7 (6 of which on diabetes); the characteristics of those studies are summarized in Table 1. Funnel plot analysis on 6-month trials on diabetes (Figure 2) did not reveal any major publication/disclosure bias for BMI, as confirmed by Kendall's tau ( $t = 0.14, P = 0.36$ ) and fail-safe  $N$  (number of missing studies that would bring  $P > 0.05$ : 733).  $I^2$  for BMI at 6 months was 83.6 ( $P < 0.001$ ).

**3.1. Results at 6 Months.** Only two trials [15, 18] in subjects with obesity not associated with diabetes reported

a significant ( $P = 0.002$ ) BMI reduction of 1.6 (0.6–2.5)  $\text{kg/m}^2$  in comparison with placebo). One further trial, which enrolled patients with type 2 diabetes, had been designed for the assessment of weight reduction with exenatide as the principal outcome [19], with similar results.

In the 19 trials performed in patients with diabetes, GLP-1 receptor agonists were associated with a significantly lower BMI at 6 months in comparison with placebo and with any active glucose-lowering agent, with the exception of the only 2 available head-to-head comparisons with thiazolidinediones. No differences in the weight-reducing effects were observed between exenatide and liraglutide (Figure 3(a)). A subgroup analysis of placebo-controlled trials was performed on the basis of the minimum BMI chosen as inclusion criterion; in trials excluding ( $N = 4$ ) or including ( $N = 5$ ) nonoverweight ( $\text{BMI} < 25 \text{ kg/m}^2$ ), the difference in 6-month BMI between active treatment and control groups was  $-1.0 [-1.6; -0.4]$  and  $-0.8 [-1.3; -0.3] \text{ kg/m}^2$ , respectively (both  $P < 0.001$ ).

For 18 out of 19 of those trials, the principal endpoint was HbA1c, which was significantly reduced by GLP-1 receptor agonists in comparison with placebo, DPP4 inhibitors, and thiazolidinediones, whereas differences with respect to sulfonylureas and insulin were not statistically significant (Figure 3(b)).

Metaregression analysis was performed on all placebo-controlled trials, including those on nondiabetic individuals, irrespective of the principal endpoint of the study. In the 11 available trials, mean baseline BMI, age, and duration of diabetes (in the 9 trials on patients with diabetes) were not significantly correlated with treatment effect on BMI.

**3.2. Results at 12 Months.** Results on BMI at 12 months were available in 7 trials, 6 of which were performed in patients with diabetes. The only one trial [14] enrolling subjects without diabetes, which had weight loss as its principal endpoint, liraglutide, induced a significant reduction of weight in comparison with placebo ( $-1.2 [-2.3; -0.1] \text{ kg/m}^2$  in 1-year BMI;  $P = 0.04$ ). The results of the other 6 trials, all with active comparators, are summarized in Table 2. In these studies, a further reduction of body weight was observed after the first six months of treatment. Similar results were obtained when the only trial which did not report 6-month BMI [14] was excluded from the analysis (data not shown).

#### 4. Discussion

The few available trials designed with weight loss as the principal endpoint and enrolling nondiabetic patients with obesity have shown that GLP-1 receptor agonists have a potential use as drugs for the treatment of overweight [14, 15]. Similar results were obtained in a trial on overweight patients with polycystic ovary syndrome, in which restoration of menstrual cycles was the principal endpoint [20]. The much wider evidence collected in subjects with type 2 diabetes confirms this effect, as previously reported [6, 18]. This action is consistent across trials, and it cannot


TABLE 1

Study (Reference)	Number of patients (ID/C)	Comparator	Trial duration (wks)	Age (ys)	Duration of DM (ys)	BMI Baseline (Kg/m <sup>2</sup> )	BMI at 6-month (Kg/m <sup>2</sup> )	HbA1c baseline (%)	HbA1c at 6-month (%; ID/C)
<i>Insulin</i>									
Marre et al. [21]	234/114	Placebo	26	56	7.0	30.0	29.9/30.3	8.5	7.5/8.7
Jauck et al. [22]	242/121	Placebo	26	57	8.0	31.3	30.1/31.1	8.3	7.3/8.5
Linman et al. [23]	355/175	Placebo	26	55	9.0	33.5	33.0/33.7	8.5	7.0/7.9
Russell-Jones et al. [24]	230/114	Placebo	26	57	9.0	30.9	29.9/31.2	8.3	7.0/8.1
Jauck et al. [22] <sup>#</sup>	242/242	Glimepiride	26	57	8.0	31.1	30.1/31.6	8.3	7.3/7.4
Barber et al. [25]	498/248	Glimepiride	52	53	5.0	33.0	32.3/33.6	8.3	7.1/7.8
Marre et al. [21] <sup>#</sup>	234/232	Rosiglitazone	26	56	7.0	29.8	29.9/30.2	8.4	7.5/8.1
Tratley et al. [26]	225/219	Sitagliptin	52	55	6.0	32.8	29.9/31.5	8.4	6.9/7.3
Russell-Jones et al. [27] <sup>#</sup>	230/232	Glargine	26	57	9.0	30.3	29.9/30.9	8.3	7.0/7.2
<i>Insulin LAR</i>									
Diamant et al. [27]	233/233	Glargine	26	58	8.0	32.0	31.1/32.5	8.3	6.8/7.0
Vergenstal et al. [28]	160/165	Pioglitazone	26	52	6.0	32.0	31.2/33.0	8.5	7.2/7.4
Vergenstal et al. [28] <sup>#</sup>	160/166	Sitagliptin	26	52	6.0	32.0	31.2/31.7	8.5	7.2/7.7
<i>Insulin</i>									
<i>Obesity</i>									
Rosenstock et al. [15]	73/79	Placebo	24	46	0.0	39.5	37.8/38.8	5.6	5.6/5.7
Ilkink-Hirsch et al. [20]	20/20	Placebo	24	29	0.0	40.4	39.1/40.8	NR	NR/NR
<i>Type 2 diabetes</i>									
Moretto et al. [29]	77/78	Placebo	24	54	2.0	31.5	30.4/31.4	7.8	6.9/7.6
Buse et al. [30]	129/123	Placebo	30	55	6.3	33.3	32.4/33.8	8.6	7.8/8.7
Buse et al. [31]	138/123	Placebo	30	59	12.0	33.5	33.2/33.5	8.4	6.6/7.5
Kendall et al. [19]	241/247	Placebo	30	55	9.0	34.0	32.9/33.7	8.5	7.7/8.6
DeFronzo et al. [32]	113/113	Placebo	30	53	5.8	34.0	33.0/33.9	8.2	7.4/8.3
Derosa et al. [33]	61/62	Glibenclamide	52	56	NR	28.6	27.3/28.9	8.8	8.1/8.0
Derosa et al. [34]	57/54	Glimepiride	52	55	NR	28.4	27.5/28.5	8.7	7.9/8.1
Gallwitz et al. [35]	248/246	BiAsp	26	57	5.0	33.1	32.0/33.2	7.9	6.9/6.8
Nauck et al. [36]	253/248	BiAsp	52	59	9.9	30.4	29.9/30.5	8.6	7.5/7.6
Heine et al. [37]	282/267	Glargine	26	59	9.5	31.3	30.6/32.0	8.2	7.2/7.1
Bunck et al. [38]	36/33	Glargine	52	58	5.0	30.5	29.9/30.4	7.5	6.7/6.8


Studies with multiple comparators; NR: not reported; ID: interventional drug; C: comparator; DM: diabetes mellitus; wks: weeks.

TABLE 2: Weighted mean differences in 6- and 12-month BMI between GLP-1 receptor agonists and different active comparators.

	Number of trials	6-month BMI	P	12-month BMI	P
Overall	6	-1.2 [-1.5; -0.8]	<0.001	-1.9 [-3.0; -0.8]	<0.001
DPP-4 inhibitors	1	-1.6 [-2.6; -0.8]	<0.001	-1.7 [-2.7; -0.7]	0.001
Sulphonylureas	3	-1.4 [-2.4; -0.7]	0.001	-2.3 [-4.2; -0.5]	0.012
Insulin	2	-0.7 [-1.4; 0.0]	0.048	-1.5 [-2.1; -0.8]	<0.001



(a)



(b)

FIGURE 3: Weighted mean differences in 6-month BMI (a) and HbA1c (b) between GLP-1 receptor agonists and different active comparators or placebo, in trials performed in type 2 diabetic patients. MD: weighted mean differences; LL: lower limits; UL: upper limits.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.